152 related articles for article (PubMed ID: 27765799)
1. ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy.
Elizalde PV; Cordo Russo RI; Chervo MF; Schillaci R
Endocr Relat Cancer; 2016 Dec; 23(12):T243-T257. PubMed ID: 27765799
[TBL] [Abstract][Full Text] [Related]
2. Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?
Cordo Russo RI; Chervo MF; Madera S; Charreau EH; Elizalde PV
Horm Cancer; 2019 Jun; 10(2-3):64-70. PubMed ID: 30656558
[TBL] [Abstract][Full Text] [Related]
3. Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance.
Cordo Russo RI; Béguelin W; Díaz Flaqué MC; Proietti CJ; Venturutti L; Galigniana N; Tkach M; Guzmán P; Roa JC; O'Brien NA; Charreau EH; Schillaci R; Elizalde PV
Oncogene; 2015 Jun; 34(26):3413-28. PubMed ID: 25174405
[TBL] [Abstract][Full Text] [Related]
4. Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.
Venturutti L; Romero LV; Urtreger AJ; Chervo MF; Cordo Russo RI; Mercogliano MF; Inurrigarro G; Pereyra MG; Proietti CJ; Izzo F; Díaz Flaqué MC; Sundblad V; Roa JC; Guzmán P; Bal de Kier Joffé ED; Charreau EH; Schillaci R; Elizalde PV
Oncogene; 2016 Apr; 35(17):2208-22. PubMed ID: 26212010
[TBL] [Abstract][Full Text] [Related]
5. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.
Elster N; Collins DM; Toomey S; Crown J; Eustace AJ; Hennessy BT
Breast Cancer Res Treat; 2015 Jan; 149(1):5-15. PubMed ID: 25542271
[TBL] [Abstract][Full Text] [Related]
6. Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer.
Wolfson E; Goldenberg M; Solomon S; Frishberg A; Pinkas-Kramarski R
Oncotarget; 2016 Oct; 7(40):65320-65334. PubMed ID: 27542246
[TBL] [Abstract][Full Text] [Related]
7. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
Breast Cancer Res Treat; 2015 Oct; 153(3):493-505. PubMed ID: 26400847
[TBL] [Abstract][Full Text] [Related]
8. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
Pharmacogenomics; 2015; 16(12):1411-26. PubMed ID: 26257318
[TBL] [Abstract][Full Text] [Related]
9. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
10. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
11. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
12. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer.
Awada G; Gombos A; Aftimos P; Awada A
Expert Opin Emerg Drugs; 2016; 21(1):91-101. PubMed ID: 26817602
[TBL] [Abstract][Full Text] [Related]
13. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?
Chandarlapaty S; Modi S
J Clin Oncol; 2011 Aug; 29(23):3111-3. PubMed ID: 21730267
[No Abstract] [Full Text] [Related]
15. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.
Tan M; Yao J; Yu D
Cancer Res; 1997 Mar; 57(6):1199-205. PubMed ID: 9067293
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
[TBL] [Abstract][Full Text] [Related]
17. "Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?
Margariti N; Fox SB; Bottini A; Generali D
Breast Cancer Res Treat; 2011 Aug; 128(3):599-606. PubMed ID: 20945086
[TBL] [Abstract][Full Text] [Related]
18. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
Newby JC; Johnston SR; Smith IE; Dowsett M
Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
[TBL] [Abstract][Full Text] [Related]
19. ErbB-2 signals through Plexin-B1 to promote breast cancer metastasis.
Worzfeld T; Swiercz JM; Looso M; Straub BK; Sivaraj KK; Offermanns S
J Clin Invest; 2012 Apr; 122(4):1296-305. PubMed ID: 22378040
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
